Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glufosfamide - Eleison Pharmaceuticals

Drug Profile

Glufosfamide - Eleison Pharmaceuticals

Alternative Names: Beta-D-Glc-IPM; D 19575; Glufosfamide; β-D-Glc-IPM

Latest Information Update: 26 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baxter Oncology; German Cancer Research Center
  • Developer Baxter Oncology; Eleison Pharmaceuticals; MediBIC; Threshold Pharmaceuticals
  • Class Antineoplastics; Oxazines; Phosphoramide mustards; Small molecules
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • No development reported Solid tumours
  • Discontinued Ovarian cancer; Small cell lung cancer; Soft tissue sarcoma

Most Recent Events

  • 19 Nov 2019 Eleison Pharmaceuticals receives approval from the China Food and Drug Administration (CFDA) to begin enrollment in China for its international phase III trial in Pancreatic cancer
  • 19 Nov 2019 Eleison Pharmaceuticals plans to initiate enrollment in a phase III trial for Pancreatic cancer in China
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top